Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 08:56am CEST

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/23 TESARO INC (NASDAQ : TSRO) Might Outperform Rivals with Zejula
06/23 ASTRAZENECA : Faslodex CHMP positive opinion in 1L breast cancer
06/23 ASTRAZENECA : Faslodex (fulvestrant) receives positive CHMP opinion for use in 1..
06/22 REPORTS FROM ASTRAZENECA ADD NEW DAT : ...
06/22 INVESTIGATORS AT ASTRAZENECA ZERO IN : DLBCL, NHL and...
06/22 ASTRAZENECA : Studies from AstraZeneca Update Current Data on Inflammation (Iden..
06/22 TROVAGENE : Enters Into Agreement with AstraZeneca to Utilize Trovera® ctDNA Tes..
06/22 China Medical City incubator attracts UK interest
06/22 ASTRAZENECA : Clinical trial deems AstraZenecas Lynparza better for mutation-cau..
More news
Sector news : Pharmaceuticals - NEC
05:33pDJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
08:35a Factbox - Companies hit by global ransomware attack on June 27
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 European Ad Com backs expanded use of AstraZeneca's breast cancer med Faslode..
06/22 AstraZeneca (AZNCF)Presents At JP Morgan European Healthcare Conference - Sli..
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 AstraZeneca (AZN) Presents At 2017 Wells Fargo West Coast Energy Conference -..
Advertisement
Financials ($)
Sales 2017 21 493 M
EBIT 2017 5 890 M
Net income 2017 2 622 M
Debt 2017 12 464 M
Yield 2017 3,98%
P/E ratio 2017 31,92
P/E ratio 2018 25,40
EV / Sales 2017 4,59x
EV / Sales 2018 4,47x
Capitalization 86 089 M
More Financials
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 67,6 $
Spread / Average Target -1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA20.50%86 089
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results